Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.

Franco MaggioloRoberto GulminettiLayla PagnuccoMargherita DigaetanoSimone BenattiDaniela ValentiAnnapaola CallegaroDiego RipamontiCristina Mussini

Published in: BMC infectious diseases (2017)

Although still limited evidence exists, a dolutegravir-based dual therapy in combination with lamivudine shows promising results to be confirmed in larger controlled trials.

Keyphrases

hiv infected patients
hiv infected
antiretroviral therapy
end stage renal disease
human immunodeficiency virus
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
stem cells
patient reported outcomes
bone marrow
mesenchymal stem cells